View ValuationTactile Systems Technology 将来の成長Future 基準チェック /46Tactile Systems Technologyは、24.1%と8.4%でそれぞれ年率24.1%で利益と収益が成長すると予測される一方、EPSはgrowで23.1%年率。主要情報24.1%収益成長率23.09%EPS成長率Medical Equipment 収益成長11.9%収益成長率8.4%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日11 Aug 2026今後の成長に関する最新情報お知らせ • Aug 11Tactile Systems Technology, Inc. Updates Earnings Guidance for the Full Year of 2026Tactile Systems Technology, Inc. updated earnings guidance for the full year of 2026. For the year, the company expects total revenue in the range of $360 million to $366 million, representing growth of approximately 9% to 11% year-over-year.お知らせ • May 07Tactile Systems Technology, Inc. Updates Earnings Guidance for the Full Year Ending December 31, 2026Tactile Systems Technology, Inc. updated earnings guidance for the full year ending December 31, 2026. For the period, the company expects total revenue in the range of $360 million to $368 million, representing growth of approximately 9% to 12% year-over-year, compared to total revenue of $329.5 million in 2025. The Company’s prior 2026 guidance expectation was total revenue in the range of $357 million to $365 million, representing growth of approximately 8% to 11% year-over-year. Net income in the range of $24,697,000 to $26,137,000.お知らせ • Feb 18+ 1 more updateTactile Systems Technology, Inc. Provides Earnings Guidance for the Full Year Ending December 31, 2026Tactile Systems Technology, Inc. provided earnings guidance for the full year ended December 31, 2026. The company expects full year 2026 total revenue in the range of $357 million to $365 million, representing growth of approximately 8% to 11% year-over-year, compared to total revenue of $329.5 million in 2025. The company expects Net income to be in the range of $26,080,000 to $27,519,000.お知らせ • Nov 05Tactile Systems Technology, Inc. Updates Earning Guidance for the Full Year 2025Tactile Systems Technology, Inc. updated earning guidance for the full year 2025. For the period, the total revenue in the range of $317 million to $321 million, representing growth of approximately 8% to 10% year-over-year, compared to total revenue of $293.0 million in 2024. The Company’s prior 2025 guidance expectation was total revenue in the range of $310 million to $315 million, representing growth of approximately 6% to 8% year-over-year.お知らせ • Aug 07Tactile Systems Technology, Inc. Updates Earnings Guidance for the Full Year 2025Tactile Systems Technology, Inc. updated earnings guidance for the full year 2025. For the period, Company now expects total revenue in the range of $310 million to $315 million, representing growth of approximately 6% to 8% year-over-year, compared to total revenue of $293.0 million in 2024. The Company’s prior 2025 guidance expectation was total revenue in the range of $309 million to $315 million, representing growth of approximately 5% to 8% year-over-year.お知らせ • May 07Tactile Systems Technology, Inc. Updates Financial Guidance for Full Year Ending December 31, 2025Tactile Systems Technology, Inc. updated financial guidance for full year ending December 31, 2025. For the period, the company expects total revenue in the range of $309 million to $315 million representing growth of approximately 5% to 8% year-over-year, compared to total revenue of $293.0 million in 2024. The Company’s prior 2025 guidance expectation was total revenue in the range of $316 million to $322 million, representing growth of approximately 8% to 10% year-over-year. The company expects Net income to be in the range of $13,400,000 to $14,800,000.すべての更新を表示Recent updatesValuation Update With 7 Day Price Move • Aug 17Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to €20.38, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 17x in the Medical Equipment industry in Germany. Total returns to shareholders of 24% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €19.96 per share.Recent Insider Transactions • Aug 13CEO, President & Director recently sold €280k worth of stockOn the 10th of August, Sheri Dodd sold around 11k shares on-market at roughly €25.49 per share. This transaction amounted to 11% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Sheri has been a net seller over the last 12 months, reducing personal holdings by €915k.Reported Earnings • Aug 11Second quarter 2026 earnings released: EPS: US$0.34 (vs US$0.14 in 2Q 2025)Second quarter 2026 results: EPS: US$0.34 (up from US$0.14 in 2Q 2025). Revenue: US$85.7m (up 8.6% from 2Q 2025). Net income: US$7.79m (up 142% from 2Q 2025). Profit margin: 9.1% (up from 4.1% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 10% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Aug 11Tactile Systems Technology, Inc. Updates Earnings Guidance for the Full Year of 2026Tactile Systems Technology, Inc. updated earnings guidance for the full year of 2026. For the year, the company expects total revenue in the range of $360 million to $366 million, representing growth of approximately 9% to 11% year-over-year.お知らせ • Jul 23Tactile Systems Technology, Inc. to Report Q2, 2026 Results on Aug 10, 2026Tactile Systems Technology, Inc. announced that they will report Q2, 2026 results After-Market on Aug 10, 2026Valuation Update With 7 Day Price Move • Jun 29Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €26.56, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 17x in the Medical Equipment industry in Germany. Total returns to shareholders of 19% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €40.69 per share.お知らせ • Jun 29Tactile Systems Technology, Inc.(NasdaqGM:TCMD) dropped from Russell 2000 Defensive IndexTactile Systems Technology, Inc.(NasdaqGM:TCMD) dropped from Russell 2000 Defensive Indexお知らせ • Jun 03Tactile Systems Technology Announces Full Commercial Launch of Next-Generation Afflovest High-Frequency Chest Wall Oscillation Therapy SystemTactile Systems Technology announced full commercial launch of its next-generation AffloVest high-frequency chest wall oscillation (HFCWO) therapy system. The next-generation system maintains its indication for use as a treatment option for chronic neuromuscular and respiratory conditions, including cystic fibrosis and bronchiectasis, across pediatric and geriatric populations, while introducing enhancements to patient comfort, ease of use, and connected care capabilities to support long-term therapy adherence. Effective management of chronic respiratory conditions requires a multimodal approach in which airway clearance plays a critical, complementary role alongside other therapies, including pharmacological agents. While these medications target inflammation and infection, they do not directly address retained mucus, one of the primary drivers of impaired lung function and disease progression. HFCWO therapy, including AffloVest, mechanically mobilizes and facilitates removal of secretions to improve ventilation and support overall respiratory health, and published clinical literature demonstrates its ability to enhance mucus transport and reduce secretion burden. Based on feedback from patients, clinicians, and durable medical equipment (DME) partners, the next-generation AffloVest was intentionally designed with a focus on simplifying setup and improving the overall treatment experience. The new system features a lighter and more adjustable vest than its predecessor to accommodate a broad range of patient ages and body types. Paired with a redesigned controller built for intuitive navigation, AffloVest is now easier to put on, simpler to operate, and more comfortable to wear at home and on the go. The next-generation AffloVest also offers built-in Wi-Fi and Bluetooth connectivity, enabling patients to visualize their treatment progress and stay engaged with therapy, while equipping clinicians with real-world data needed to have more informed, personalized treatment discussions. DME providers also gain access to therapy utilization data that supports patient care and reimbursement requirements with payers.お知らせ • May 07Tactile Systems Technology, Inc. Updates Earnings Guidance for the Full Year Ending December 31, 2026Tactile Systems Technology, Inc. updated earnings guidance for the full year ending December 31, 2026. For the period, the company expects total revenue in the range of $360 million to $368 million, representing growth of approximately 9% to 12% year-over-year, compared to total revenue of $329.5 million in 2025. The Company’s prior 2026 guidance expectation was total revenue in the range of $357 million to $365 million, representing growth of approximately 8% to 11% year-over-year. Net income in the range of $24,697,000 to $26,137,000.お知らせ • Apr 21Tactile Systems Technology, Inc. to Report Q1, 2026 Results on May 04, 2026Tactile Systems Technology, Inc. announced that they will report Q1, 2026 results After-Market on May 04, 2026お知らせ • Mar 10Tactile Systems Technology, Inc. Announces Appointment of Andrea A. Pearson to Board of Directors and Member of the Compliance and Reimbursement Committee and of the Nominating and Corporate Governance Committee, Effective March 9, 2026On March 4, 2026, the board of directors of Tactile Systems Technology, Inc. announced the appointment of Andrea Pearson to the Company’s Board of Directors (“Board”) and as a member of the Compliance & Reimbursement and Nominating & Corporate Governance Committees, effective March 9, 2026. Ms. Pearson is an accomplished senior executive and growth strategist with deep expertise in scaling healthcare organizations. Her extensive experience spans more than 25 years and includes exposure to product development, customer acquisition, branding, marketing communications, and public relations. Most recently, she served as Growth Advisor and Chief Marketing Officer at Harbor Health, a healthcare organization that integrates clinical care with health insurance coverage. Previously, she was Chief Growth Officer, and, before that, Chief Marketing Officer at DispatchHealth, a leader in at-home, hospital-level care, where she architected the company’s growth strategy, scaling the business from two to more than 50 U.S. markets while driving a 30x increase in revenue. Prior to DispatchHealth, Ms. Pearson held multiple executive roles at HealthGrades, a leading online platform connecting patients with healthcare providers, including Chief Marketing Officer and Executive Vice President and General Manager. As Chief Marketing Officer, she grew the consumer audience from one million monthly to one million daily visitors. Her earlier career experience includes 10 years of increasing responsibility across product development, marketing, and general management roles.お知らせ • Feb 19Tactile Systems Technology, Inc., Annual General Meeting, May 06, 2026Tactile Systems Technology, Inc., Annual General Meeting, May 06, 2026.お知らせ • Feb 18+ 1 more updateTactile Systems Technology, Inc. Provides Earnings Guidance for the Full Year Ending December 31, 2026Tactile Systems Technology, Inc. provided earnings guidance for the full year ended December 31, 2026. The company expects full year 2026 total revenue in the range of $357 million to $365 million, representing growth of approximately 8% to 11% year-over-year, compared to total revenue of $329.5 million in 2025. The company expects Net income to be in the range of $26,080,000 to $27,519,000.お知らせ • Feb 04Tactile Systems Technology, Inc. to Report Q4, 2025 Results on Feb 17, 2026Tactile Systems Technology, Inc. announced that they will report Q4, 2025 results at 4:00 PM, US Eastern Standard Time on Feb 17, 2026お知らせ • Nov 05Tactile Systems Technology, Inc. Updates Earning Guidance for the Full Year 2025Tactile Systems Technology, Inc. updated earning guidance for the full year 2025. For the period, the total revenue in the range of $317 million to $321 million, representing growth of approximately 8% to 10% year-over-year, compared to total revenue of $293.0 million in 2024. The Company’s prior 2025 guidance expectation was total revenue in the range of $310 million to $315 million, representing growth of approximately 6% to 8% year-over-year.お知らせ • Nov 04Tactile Systems Technology, Inc. (NasdaqGM:TCMD) announces an Equity Buyback for $25 million worth of its shares.Tactile Systems Technology, Inc. (NasdaqGM:TCMD) announces an share repurchase program. Under the program, the company will repurchase up to $25 million worth of its common stock. The program will be financed via existing cash and future cash flows. The repurchase program is valid till November 3, 2027.お知らせ • Oct 30Tactile Systems Technology, Inc. Announces the Presentation of New Six-Month Clinical DataTactile Systems Technology, Inc. announced the presentation of new six-month clinical data during the late-breaking poster session at the American Congress of Rehabilitation Medicine (ACRM) 102nd Annual Fall Conference demonstrating sustained clinical benefits of Flexitouch®? Plus as a first-line therapy for treating patients with head and neck cancer-related lymphedema. The six-month analysis, drawn from a large randomized controlled trial, showed improvement in lymphedema symptom burden for participants in both the advanced pneumatic compression device (APCD) study arm, consisting of treatment with Flexitouch Plus, and the usual care study arm, which included therapist-guided multimodal treatment. Symptom severity was based on scoring from disease-specific patient-reported symptom surveys. Welling improvements were also observed in objective clinical assessments, including CT imaging. Highlights from the six-month results include: Flexitouch Plus demonstrated reduced internal swelling at the majority of anatomical sites (13 of 19), with statistically significant improvement achieved in the base of tongue (p=0.008) and arytenoids (p=0.023); Clinician-reported outcome measures of both internal (Endoscopy Modified Patterson Scale) and external soft tissue swelling favored Flexitouch Plus over usual care; Significant improvement in epiglottic thickness and prevertebral soft tissue thickness at C3 in both groups at six months; The initial patient benefit of Flexitouch Plus and usual care was maintained over the six-month study timeframe; and Both groups demonstrated sustained improvement in symptom burden over the six-month study period. The new long-term results follow two-month data released at ASCO in June 2025 and are drawn from the largest prospective, randomized controlled study ever conducted among head and neck cancer survivors in the United States, which enrolled 236 patients across 10 academic and community-based centers. The sustained patient benefits associated with Flexitouch Plus, as demonstrated in the six-month results, combined with the early improvements seen at two months, are clinically important for head and neck lymphedema patients and the providers who treat them. Not only is therapist-guided care limited in the U.S., but payer coverage policies have restricted access to Flexitouch Plus in this population.お知らせ • Oct 21Tactile Systems Technology, Inc. to Report Q3, 2025 Results on Nov 03, 2025Tactile Systems Technology, Inc. announced that they will report Q3, 2025 results After-Market on Nov 03, 2025お知らせ • Aug 07Tactile Systems Technology, Inc. Updates Earnings Guidance for the Full Year 2025Tactile Systems Technology, Inc. updated earnings guidance for the full year 2025. For the period, Company now expects total revenue in the range of $310 million to $315 million, representing growth of approximately 6% to 8% year-over-year, compared to total revenue of $293.0 million in 2024. The Company’s prior 2025 guidance expectation was total revenue in the range of $309 million to $315 million, representing growth of approximately 5% to 8% year-over-year.お知らせ • Jul 22Tactile Systems Technology, Inc. to Report Q2, 2025 Results on Aug 04, 2025Tactile Systems Technology, Inc. announced that they will report Q2, 2025 results After-Market on Aug 04, 2025お知らせ • Jun 04Tactile Systems Technology, Inc. Announces the Presentation of New Clinical Data at the American Society of Clinical Oncology 2025 Annual MeetingTactile Systems Technology, Inc. announced the presentation of new clinical data at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting that demonstrates significant clinical and quality-of-life benefits associated with use of the Company's Flexitouch Plus versus usual care in treating patients with head and neck cancer-related lymphedema. The two-month analysis featured data from the Company's six-month clinical trial, which examines the effectiveness of Flexitouch Plus, an advanced pneumatic compression device (APCD), versus usual care in treating head and neck cancer survivors. The study includes 236 subjects across 10 academic and community sites, representing the largest prospective, randomized controlled study on this patient group ever conducted in the United States. Outcome measures include changes in disease-specific patient-reported symptom survey scores and objective clinical assessments, including CT imaging. Two-month data demonstrated that usual care and APCD are similarly effective treatment modalities for head and neck lymphedema. Specific areas of differentiation showed: Usual care participants took an average of 29.8 days to begin therapist guided lymphedema treatment (TGLT), while APCD participants received their device in 17.9 days; Of participants randomized to usual care, only 71% received TGLT compared to 94.9% of those in the APCD group; APCD participants had significant reduction in swelling via digital photography and total Head and Neck Cancer Related Lymphedema and Fibrosis Grading (HN-LEFG) scores while usual care participants exhibited incremental improvements; and Self-reported symptom improvement occurred in both groups, with APCD demonstrating significant improvement on three of the six health-related quality-of-life sub scales. Flexitouch Plus is an FDA-cleared therapy designed for at-home treatment of lymphedema, chronic venous insufficiency (CVI), and chronic wounds.お知らせ • May 07Tactile Systems Technology, Inc. Updates Financial Guidance for Full Year Ending December 31, 2025Tactile Systems Technology, Inc. updated financial guidance for full year ending December 31, 2025. For the period, the company expects total revenue in the range of $309 million to $315 million representing growth of approximately 5% to 8% year-over-year, compared to total revenue of $293.0 million in 2024. The Company’s prior 2025 guidance expectation was total revenue in the range of $316 million to $322 million, representing growth of approximately 8% to 10% year-over-year. The company expects Net income to be in the range of $13,400,000 to $14,800,000.お知らせ • Apr 22Tactile Systems Technology, Inc. to Report Q1, 2025 Results on May 05, 2025Tactile Systems Technology, Inc. announced that they will report Q1, 2025 results After-Market on May 05, 2025お知らせ • Mar 31Tactile Systems Technology, Inc., Annual General Meeting, May 07, 2025Tactile Systems Technology, Inc., Annual General Meeting, May 07, 2025. Location: wells fargo center, suite 2200, 90 south seventh st, minnesota 55402., minneapolis United Statesお知らせ • Feb 19Tactile Systems Technology, Inc. Provides Earnings Guidance for the Year Ending December 31, 2025Tactile Systems Technology, Inc. provided earnings guidance for the year ending December 31, 2025. The Company expects full year 2025 total revenue in the range of $316 million to $322 million, representing growth of approximately 8% to 10% year-over-year, compared to total revenue of $293.0 million in 2024. The company expects Net income to be in the range of $15,750,000 to $17,150,000.お知らせ • Feb 06Tactile Systems Technology, Inc. to Report Q4, 2024 Results on Feb 18, 2025Tactile Systems Technology, Inc. announced that they will report Q4, 2024 results After-Market on Feb 18, 2025お知らせ • Feb 04Tactile Medical Expands Launch of Nimbl to Include Patients with Lower Extremity LymphedemaTactile Systems Technology, Inc. announced that Nimbl, its next-generation pneumatic compression platform, is now commercially available throughout the United States (U.S.) for the treatment of both upper and lower extremity lymphedema. Nimbl's expanded availability to include lower extremity conditions ("phlebolymphedema") follows its commercial introduction in October 2024, initially focused on treating patients suffering from upper extremity lymphedema". Nimbl is the smallest pneumatic compression device (PCD) of its kind, featuring a compact controller that is 68% lighter and 40% smaller than the Company's current generation PCD. The lower extremity garment uses 94% lessosing, making the device easy to transport and manage. Nimbl is the only basic PCD with Bluetooth®? connectivity, providing patients a way to track their treatments and symptom progress with the Company's free Kylee™? digital application.お知らせ • Jan 13Tactile Systems Technology, Inc. Announces the Appointment of Laura King to the Board of Directors and as A Member of the Audit and Compliance & Reimbursement CommitteesTactile Systems Technology, Inc. announced the appointment of Laura King to the Company’s Board of Directors (“Board”) and as a member of the Audit and Compliance & Reimbursement Committees, effective January 13, 2025. Ms. King is a seasoned healthcare executive with a proven track record of leadership and developing innovative products that enhance patient care. Her extensive experience includes a 22-year career at General Electric Company (GE), where she served as a Company Officer in her role as President & CEO of GE Healthcare’s Global Interventional Business, which provided clinical solutions enabling minimally invasive procedures in cardiology, interventional radiology, and surgery. Her earlier experience at GE included various senior level audit and finance roles, including Chief Information Officer & Chief Financial Officer, Consumer & ECM Motors. Ms. King is currently co-founder & CEO of BiaCure, Inc., a developer of effective treatments for nail fungus. Previously, she co-founded and served as CEO of Elucent Medical, a developer of a real-time surgical navigation platform that has positively impacted over 10,000 breast cancer patients. Ms. King also served as President & CEO of NeuWave Medical, a manufacturer and marketer of a minimally invasive soft tissue microwave ablation system to destroy tumor cells, which was acquired by Johnson & Johnson’s MedTech division.Valuation Update With 7 Day Price Move • Nov 13Investor sentiment improves as stock rises 20%After last week's 20% share price gain to €14.70, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 23x in the Medical Equipment industry in Germany. Total loss to shareholders of 41% over the past three years.New Risk • Nov 06New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 5.4% Last year net profit margin: 9.2% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (5.4% net profit margin). Shareholders have been diluted in the past year (2.3% increase in shares outstanding).お知らせ • Nov 06Tactile Systems Technology, Inc. (NasdaqGM:TCMD) announces an Equity Buyback for $30 million worth of its shares.Tactile Systems Technology, Inc. (NasdaqGM:TCMD) announces an share repurchase program. Under the program, the company will repurchase up to $30 million worth of its common stock. The program will be financed via existing cash and cash equivalents and future cash flows. The repurchase program is valid till October 31, 2026.お知らせ • Nov 05Tactile Systems Technology, Inc. Revises Revenue Guidance for the Year 2024Tactile Systems Technology, Inc. revised revenue guidance for the year 2024. The Company is updating its 2024 financial outlook and now expects full year 2024 total revenue in the range of $292 million to $295 million, representing growth of approximately 6% to 8% year-over-year, compared to total revenue of $274.4 million in 2023. The Company’s prior 2024 guidance expectation was total revenue in the range of $293 million to $298 million, representing growth of approximately 7% to 9%.お知らせ • Oct 22Tactile Systems Technology, Inc. to Report Q3, 2024 Results on Nov 04, 2024Tactile Systems Technology, Inc. announced that they will report Q3, 2024 results After-Market on Nov 04, 2024お知らせ • Oct 02Tactile Systems Technology, Inc. Launches Next-Generation Nimbl™ Lymphedema PlatformTactile Systems Technology, Inc. announced that Nimbl, its next-generation pneumatic compression platform, is now commercially available throughout the United States for the treatment of upper extremity lymphedema. Nimbl, which is significantly smaller and lighter than previous device iterations, is indicated as a treatment option for patients with both upper and lower extremity lymphedema, chronic edema, venous insufficiency, and wound healing. Nimbl received U.S Food & Drug Administration (FDA) 510(k) clearance in June 2024 and Pricing, Data Analysis, and Coding (PDAC) approval from the Centers for Medicare & Medicaid Services (CMS) in September 2024. The Company expects to make Nimbl commercially available for patients with lower extremity conditions in the coming months. Nimbl is 68% lighter, 40% smaller, and uses 33% less hosing than the Company’s current generation basic pneumatic compression device (PCD). Its compact design is the smallest PCD of its kind, making it an ideal therapy for daily use at home or on the go. In addition to the patient centric feature enhancements, Nimbl also offers connectivity to the Company’s free Kylee™ digital application, providing patients a simple way to track their usage and change in symptoms, and to share results with their care team. Convenient accessories are available for purchase including a rechargeable battery and custom-designed travel bag.New Risk • Sep 26New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 1.2% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 1.2% per year for the foreseeable future. Minor Risk Shareholders have been diluted in the past year (2.2% increase in shares outstanding).お知らせ • Sep 16Tactile Medical Receives PDAC Approval for Nimbl Lymphedema PlatformTactile Systems Technology, Inc. announced that the Pricing, Data Analysis, and Coding (PDAC) contractor for the Centers for Medicare & Medicaid Services (CMS) has approved the use of Healthcare Common Procedure Coding System (HCPCS) code E0651 for billing the Durable Medical Equipment Medicare Administrative Contractors for Nimbl, the Company’s next-generation pneumatic compression platform. PDAC approval is subsequent to the receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) in June 2024. The Company will make Nimbl commercially available in the United States in the coming weeks. Nimbl is the next generation of the Company’s basic lymphedema compression solution and is indicated for the treatment of lymphedema, chronic edema, venous insufficiency, and wound healing. The device features several key patient-friendly enhancements over prior generations, including a 40% and 68% reduction in size and weight, respectively, making it more portable and ideal for active lifestyles. Nimbl offers connectivity to the Company’s Kylee digital application, enabling patients to actively track their therapy progress and share results with their care team.New Risk • Aug 15New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: €57k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (2.2% increase in shares outstanding). Significant insider selling over the past 3 months (€57k sold).Reported Earnings • Aug 06Second quarter 2024 earnings released: EPS: US$0.18 (vs US$0.004 loss in 2Q 2023)Second quarter 2024 results: EPS: US$0.18 (up from US$0.004 loss in 2Q 2023). Revenue: US$73.2m (up 7.1% from 2Q 2023). Net income: US$4.30m (up US$4.40m from 2Q 2023). Profit margin: 5.9% (up from net loss in 2Q 2023). Revenue is forecast to grow 10.0% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.お知らせ • Aug 06+ 1 more updateTactile Systems Technology, Inc. Revises Financial Guidance for the Full Year 2024Tactile Systems Technology, Inc. revised financial guidance for the full year 2024. The Company is updating its 2024 financial outlook and now expects full year 2024 total revenue in the range of $293 million to $298 million, representing growth of approximately 7% to 9% year-over-year, compared to total revenue of $274.4 million in 2023. The Company’s prior 2024 guidance expectation was total revenue in the range of $300 million to $305 million, representing growth of approximately 9% to 11%.お知らせ • Jul 23Tactile Systems Technology, Inc. to Report Q2, 2024 Results on Aug 05, 2024Tactile Systems Technology, Inc. announced that they will report Q2, 2024 results After-Market on Aug 05, 2024New Risk • May 07New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 21% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (2.3% increase in shares outstanding).Reported Earnings • May 07First quarter 2024 earnings released: US$0.093 loss per share (vs US$0.089 loss in 1Q 2023)First quarter 2024 results: US$0.093 loss per share (further deteriorated from US$0.089 loss in 1Q 2023). Revenue: US$61.1m (up 3.8% from 1Q 2023). Net loss: US$2.21m (loss widened 17% from 1Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.お知らせ • Apr 24+ 1 more updateTactile Systems Technology, Inc. Provides Preliminary Revenue Guidance for the First Quarter 2024Tactile Systems Technology, Inc. provided preliminary revenue guidance for the first quarter 2024. Unaudited total revenue for the first quarter of 2024 is expected to be approximately $61 million, compared to $58.8 million in the first quarter of 2023.お知らせ • Apr 16Tactile Systems Technology, Inc. to Report Q1, 2024 Results on May 06, 2024Tactile Systems Technology, Inc. announced that they will report Q1, 2024 results After-Market on May 06, 2024お知らせ • Mar 28Tactile Systems Technology, Inc., Annual General Meeting, May 08, 2024Tactile Systems Technology, Inc., Annual General Meeting, May 08, 2024, at 09:00 Central Daylight. Location: Wells Fargo Center 90 South Seventh St., Ste 2200 Mineapolis Minnesota United States Agenda: To elect eight directors; to ratify the appointment of Grant Thornton LLP as our independent registered public accounting firm for the year ending December 31, 2024; to approve, on an advisory basis, the 2023 compensation of our named executive officers as disclosed in the accompanying Proxy Statement; to approve an amendment to our Amended and Restated Certificate of Incorporation to allow for exculpation of officers as permitted by Delaware law; and to transact such other business as may properly come before the meeting or at any and all adjournments or postponements thereof.Reported Earnings • Feb 21Full year 2023 earnings released: EPS: US$1.24 (vs US$0.89 loss in FY 2022)Full year 2023 results: EPS: US$1.24 (up from US$0.89 loss in FY 2022). Revenue: US$274.4m (up 11% from FY 2022). Net income: US$28.5m (up US$46.4m from FY 2022). Profit margin: 10% (up from net loss in FY 2022). The move to profitability was primarily driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.お知らせ • Feb 20Tactile Systems Technology, Inc. Provides Revenue Guidance for the Full Year 2024Tactile Systems Technology, Inc. provided revenue guidance for the full year 2024. For the year, the company expected total revenue in the range of $300.0 million to $305.0 million, representing growth of approximately 9% to 11% year-over-year, compared to total revenue of $274.4 million in 2023.お知らせ • Jan 30Tactile Systems Technology, Inc. to Report Q4, 2023 Results on Feb 20, 2024Tactile Systems Technology, Inc. announced that they will report Q4, 2023 results Pre-Market on Feb 20, 2024Valuation Update With 7 Day Price Move • Nov 27Investor sentiment improves as stock rises 22%After last week's 22% share price gain to €12.60, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 24x in the Medical Equipment industry in Germany. Total loss to shareholders of 64% over the past three years.Valuation Update With 7 Day Price Move • Nov 13Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to €9.80, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 24x in the Medical Equipment industry in Germany. Total loss to shareholders of 73% over the past three years.New Risk • Nov 07New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 6.3% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings are forecast to decline by an average of 6.3% per year for the foreseeable future. Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (17% increase in shares outstanding).Reported Earnings • Nov 07Third quarter 2023 earnings released: EPS: US$0.95 (vs US$0.11 loss in 3Q 2022)Third quarter 2023 results: EPS: US$0.95 (up from US$0.11 loss in 3Q 2022). Revenue: US$69.6m (up 6.6% from 3Q 2022). Net income: US$22.3m (up US$24.6m from 3Q 2022). Profit margin: 32% (up from net loss in 3Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 27% per year, which means it is performing significantly worse than earnings.お知らせ • Nov 07Tactile Systems Technology, Inc. Updates Earnings Guidance for the Full Year 2023Tactile Systems Technology, Inc. updated earnings guidance for the full year 2023. For the period, the Company expects full year 2023 total revenue in the range of $273.0 million to $277.0 million, representing growth of approximately 11% to 12% year-over-year. The Company’s prior 2023 revenue guidance expectation was total revenue in the range of $274.0 million to $278.0 million, representing growth of approximately 11% to 13% year-over-year.New Risk • Nov 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 8.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.9% average weekly change). Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (17% increase in shares outstanding).お知らせ • Oct 05Tactile Systems Technology, Inc. to Report Q3, 2023 Results on Nov 06, 2023Tactile Systems Technology, Inc. announced that they will report Q3, 2023 results After-Market on Nov 06, 2023お知らせ • Aug 09Tactile Systems Technology, Inc. Revises Earnings Guidance for the Full Year 2023Tactile Systems Technology, Inc. revised earnings guidance for the full year 2023. For the year, the company expects total revenue in the range of $274 million to $278 million, representing growth of approximately 11% to 13% year-over-year. The Company's prior 2023 revenue guidance expectations called for total revenue in the range of $271 million to $275 million, representing growth of approximately 10% to 11.5% year-over-year.Reported Earnings • Aug 08Second quarter 2023 earnings released: US$0.004 loss per share (vs US$0.23 loss in 2Q 2022)Second quarter 2023 results: US$0.004 loss per share (improved from US$0.23 loss in 2Q 2022). Revenue: US$68.3m (up 15% from 2Q 2022). Net loss: US$100.0k (loss narrowed 98% from 2Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings.お知らせ • Jul 21Tactile Systems Technology, Inc. Announces Senior Vice President of Sales ChangesTactile Systems Technology, Inc. announced the appointment of Sherri Ferstler to the position of Senior Vice President of Sales, effective July 31, 2023. Ms. Ferstler will succeed Eric Pauls, who will be resigning from the Company, effective July 28, 2023. Prior to joining Tactile Medical, Ms. Ferstler served as Vice President Sales, North America for Johnson & Johnson Vision since 2016. In this position, Ms. Ferstler led the field & inside sales teams, strategic accounts & training functions selling Acuvue brand contact lenses across multiple channels. Ms. Ferstler began her career in 1992 with Parke-Davis Pharmaceuticals where she served in a variety of sales, sales management and training and development roles. She joined Pfizer in 2000, serving as a district sales manager for all branded pharmaceutical products until 2003, then as Director of Division Operations and as a regional manager for Pfizer’s Urology and Respiratory product portfolios. From 2007 to 2016, Ms. Ferstler led regional and national sales teams for Endo Pharmaceuticals, Bayer Diabetes Care and Mylan Pharmaceuticals. Ms. Ferstler holds Bachelor of Arts in Psychology from the State University of New York College at Buffalo.Buying Opportunity • Jul 07Now 22% undervaluedOver the last 90 days, the stock is up 37%. The fair value is estimated to be €27.12, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Meanwhile, the company became loss making.お知らせ • Jun 30Tactile Systems Technology, Inc. to Report Q2, 2023 Results on Aug 07, 2023Tactile Systems Technology, Inc. announced that they will report Q2, 2023 results After-Market on Aug 07, 2023お知らせ • Jun 25Tactile Systems Technology, Inc.(NasdaqGM:TCMD) dropped from Russell Small Cap Comp Value IndexTactile Systems Technology, Inc.(NasdaqGM:TCMD) dropped from Russell Small Cap Comp Value IndexBuying Opportunity • Jun 13Now 21% undervaluedOver the last 90 days, the stock is up 42%. The fair value is estimated to be €27.46, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Meanwhile, the company became loss making.お知らせ • Jun 02Robbins Geller Rudman & Dowd LLP Announces Proposed Settlement in the Tactile Systems Technology, Inc. Securities LitigationRobbins Geller Rudman & Dowd LLP announced the following update regarding the Tactile Systems Technology, Inc. Securities Litigation: that a hearing will be held on August 23, 2023, (1) the proposed settlement (the “Settlement”) of the above-captioned action as set forth in the Stipulation of Settlement (“Stipulation”)1 for $5,000,000 in cash should be approved by the Court as fair, reasonable, and adequate; (2) the Judgment as provided under the Stipulation should be entered dismissing the Litigation with prejudice; (3) to award Lead Counsel attorneys’ fees and expenses out of the Settlement Fund (as defined in the Notice of Pendency and Proposed Settlement of Class Action (“Notice”), which is discussed below), and, if so, in what amounts; and (4) the Plan of Allocation should be approved by the Court as fair, reasonable, and adequate.Reported Earnings • May 09First quarter 2023 earnings released: US$0.089 loss per share (vs US$0.78 loss in 1Q 2022)First quarter 2023 results: US$0.089 loss per share (improved from US$0.78 loss in 1Q 2022). Revenue: US$58.8m (up 23% from 1Q 2022). Net loss: US$1.89m (loss narrowed 88% from 1Q 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 29% per year, which means it has not declined as severely as earnings.お知らせ • May 09Tactile Systems Technology, Inc. Provides Revenue Guidance for Full Year 2023Tactile Systems Technology, Inc. provided revenue guidance for the full year 2023. For the period, the company expects total revenue in the range of approximately $271.0 million to $275.0 million, representing growth of approximately 10% to 11.5% year-over-year. The Company’s prior 2023 revenue guidance expectations called for total revenue in the range of $269.0 million to $273.0 million, representing growth of approximately 9% to 11% year-over-year.Recent Insider Transactions • Mar 05President recently sold €101k worth of stockOn the 28th of February, Daniel Reuvers sold around 7k shares on-market at roughly €14.32 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Daniel has been a net seller over the last 12 months, reducing personal holdings by €111k.Breakeven Date Change • Feb 22Forecast breakeven date moved forward to 2023The 3 analysts covering Tactile Systems Technology previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of US$2.22m in 2023. Earnings growth of 148% is required to achieve expected profit on schedule.Reported Earnings • Feb 22Full year 2022 earnings released: US$0.89 loss per share (vs US$0.60 loss in FY 2021)Full year 2022 results: US$0.89 loss per share (further deteriorated from US$0.60 loss in FY 2021). Revenue: US$246.8m (up 19% from FY 2021). Net loss: US$17.9m (loss widened 51% from FY 2021). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 49 percentage points per year, which is a significant difference in performance.お知らせ • Feb 02Tactile Systems Technology, Inc. to Report Q4, 2022 Results on Feb 21, 2023Tactile Systems Technology, Inc. announced that they will report Q4, 2022 results Pre-Market on Feb 21, 2023お知らせ • Jan 06Tactile Systems Technology, Inc. Appoints Carmen Volkart to Board of DirectorsTactile Systems Technology, Inc. announced the appointment of Carmen Volkart to the Company’s Board of Directors (“Board”), effective January 5, 2023. Since 2018, Carmen Volkart has served as the Chief Financial Officer of NatureWorks LLC, a privately-held advanced materials company and developer of renewably sourced polymers and chemicals. Prior to joining NatureWorks, she served as the Chief Financial Officer of NxThera, Inc., a privately-held medical device company focused on the treatment of benign prostatic hyperplasia, from 2012 until its acquisition by Boston Scientific in 2018. From 2010 to 2012, Ms. Volkart served as Chief Financial Officer of Tornier, N.V., a medical device company focused on treating musculoskeletal injuries and disorders of the shoulder, elbow, wrist, hand, ankle and foot. She led Tornier through a successful initial public offering in 2011. Prior to joining Tornier, Ms. Volkart served as Chief Operating and Financial Officer, Corporate Secretary, Compliance Officer and Treasurer of Spine Wave, Inc., a privately-held medical device company focused on minimally invasive spine surgery and expandable interbody devices, from 2006 to 2010. From 2004 to 2006, Ms. Volkart served as Executive Vice President, and Chief Financial Officer of American Medical Systems, Inc., a publicly traded medical device company focused on male and female pelvic health. Her career history also includes significant experience in various financial and managerial positions at both Medtronic, Inc., from 1992 to 2004, and Honeywell, Inc., from 1982 to 1992.お知らせ • Nov 22Tactile Systems Technology, Inc. Reaches Agreement to Settle Securities Class Action LawsuitTactile Systems Technology, Inc. announced that it has entered into a Memorandum of Understanding to settle the previously disclosed securities class action lawsuit pending in the United States District Court for the District of Minnesota titled Mart v. Tactile Systems Technology, Inc. et al. The Company does not expect to fund any portion of the cash payments made in connection with the settlement. The settlement does not constitute an admission of any liability or wrongdoing by Tactile Medical or any of its current or former officers or directors. Nonetheless, it is desirable and beneficial to Tactile Medical and its stockholders to settle the lawsuit to avoid the costs, burden and distraction of continued litigation. The settlement framework provides for payment of a total of $5.0 million to settle claims brought on behalf of investors who purchased the Company’s common stock in the market between May 7, 2018 and June 8, 2020. The Company’s insurers are funding the settlement payment to Plaintiffs and have agreed to the terms of the MOU. The settlement is subject to the parties reaching agreement on various non-monetary terms, and court approval of the final terms will be required. The parties have agreed to negotiate in good faith to execute definitive stipulations of settlement and related documents to be filed with the court, which, among other things, will provide that upon final approval of the settlement by the court, the case will be dismissed with prejudice, with mutual releases by all parties.Board Change • Nov 16High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 5 experienced directors. No highly experienced directors. Independent Chairman Bill Burke is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Nov 09Third quarter 2022 earnings released: US$0.11 loss per share (vs US$0.17 loss in 3Q 2021)Third quarter 2022 results: US$0.11 loss per share (improved from US$0.17 loss in 3Q 2021). Revenue: US$65.3m (up 24% from 3Q 2021). Net loss: US$2.28m (loss narrowed 32% from 3Q 2021). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 47 percentage points per year, which is a significant difference in performance.お知らせ • Nov 08Tactile Systems Technology, Inc. Revises Earnings Guidance for the Year 2022Tactile Systems Technology, Inc. revised earnings guidance for the year 2022. The Company now expects full year 2022 total revenue in the range of $242.0 million to $245.0 million, representing growth of approximately 16% to 18% year-over-year, compared to total revenue of $208.1 million in 2021. The Company’s prior 2022 revenue guidance expectations called for total revenue in the range of $238.0 million to $242.0 million, representing growth of approximately 14% to 16% year-over-year.お知らせ • Sep 27Tactile Systems Technology, Inc. to Report Q3, 2022 Results on Nov 07, 2022Tactile Systems Technology, Inc. announced that they will report Q3, 2022 results After-Market on Nov 07, 2022Reported Earnings • Aug 02Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.066 profit in 2Q 2021)Second quarter 2022 results: US$0.23 loss per share (down from US$0.066 profit in 2Q 2021). Revenue: US$59.6m (up 17% from 2Q 2021). Net loss: US$4.64m (down 456% from profit in 2Q 2021). Over the next year, revenue is forecast to grow 15%, compared to a 7.3% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 42 percentage points per year, which is a significant difference in performance.お知らせ • Aug 02Tactile Systems Technology, Inc. Raises Earnings Guidance for the Full Year 2022Tactile Systems Technology, Inc. raised earnings guidance for the full year 2022. For the year, the company expected total revenue in the range of $238.0 million to $242.0 million, representing growth of approximately 14% to 16% year-over-year, compared to total revenue of $208.1 million in 2021. The Company’s prior 2022 revenue guidance expectations called for total revenue in the range of $235.0 million to $240.0 million, representing growth of approximately 13% to 15% year-over-year.お知らせ • Jul 26Tactile Medical Introduces New ComfortEase Flexitouch Plus Garments and Kylee Mobile ApplicationTactile Systems Technology, Inc. announced the full market release of its new ComfortEase™ garments, part of the Flexitouch® Plus system. In addition, Tactile Medical is putting the power of lymphedema health tracking in the palm of patients’ hands with the launch of its Kylee™ mobile application. Enhancing the Patient Experience with ComfortEase Leveraging over 18,000 points of feedback from patients and therapists, Tactile Medical redesigned the Flexitouch Plus garments to be easier to use, better fitting and more comfortable, all intended to improve patient experience and satisfaction. Together with the Flexitouch Plus controller, the ComfortEase garments provide patients with an effective system for at-home therapy and symptom relief of lymphedema, a condition which requires diligent daily management. Empowering Patients Through Digital Health Monitoring Patients using the Flexitouch Plus system, as well as those who are undiagnosed and concerned about their swelling, now have access to the Kylee mobile application. This application expands Tactile Medical’s ability to serve patients on their journey to diagnosis. Kylee, a personal lymphedema assistant, is available on both the iOS and Android platforms, and is intended to help educate, manage symptoms and support patients to help them get the most out of their therapies. The app enables users to record their symptoms and treatments, and upload photos to track changes over time. Kylee app users may also show their progress to their doctor, which can lead to more informed conversations. The free app includes Flexitouch Plus and Entre shipment and order tracking, product tutorial videos and an education library which provides helpful information about lymphedema and symptom management.お知らせ • Jul 13Tactile Systems Technology, Inc. to Report Q2, 2022 Results on Aug 01, 2022Tactile Systems Technology, Inc. announced that they will report Q2, 2022 results at 4:00 PM, US Eastern Standard Time on Aug 01, 2022お知らせ • Jun 26Tactile Systems Technology, Inc.(NasdaqGM:TCMD) dropped from Russell 2000 Defensive IndexTactile Systems Technology, Inc.(NasdaqGM:TCMD) dropped from Russell 2000 Defensive IndexBoard Change • May 12High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director David Shafer was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • May 04First quarter 2022 earnings released: US$0.78 loss per share (vs US$0.12 loss in 1Q 2021)First quarter 2022 results: US$0.78 loss per share (down from US$0.12 loss in 1Q 2021). Revenue: US$48.0m (up 12% from 1Q 2021). Net loss: US$15.6m (loss widened US$13.3m from 1Q 2021). Over the next year, revenue is forecast to grow 16%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 42 percentage points per year, which is a significant difference in performance.お知らせ • May 03Tactile Systems Technology, Inc. Reaffirms Earnings Guidance for the Year 2022Tactile Systems Technology, Inc. reaffirmed earnings guidance for the year 2022. The company continues to expect full year 2022 total revenue in the range of $235.0 million to $240.0 million, representing growth of approximately 13% to 15% year-over-year, compared to total revenue of $208.1 million in 2021.お知らせ • Apr 01Tactile Systems Technology, Inc. to Report Q1, 2022 Results on May 02, 2022Tactile Systems Technology, Inc. announced that they will report Q1, 2022 results After-Market on May 02, 2022お知らせ • Mar 29Tactile Systems Technology, Inc., Annual General Meeting, May 09, 2022Tactile Systems Technology, Inc., Annual General Meeting, May 09, 2022, at 09:00 Central Daylight. Agenda: To elect seven directors; to approve, on an advisory basis, the 2021 compensation of executive officers as disclosed in the ccompanying proxy statement; to ratify the appointment of grant thornton llp as independent registered public accounting firm for the year ending December 31, 2022; and to transact such other business as may properly come before the meeting or at any and all adjournments or postponements thereof.Reported Earnings • Feb 24Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: US$0.60 loss per share (down from US$0.032 loss in FY 2020). Revenue: US$208.1m (up 11% from FY 2020). Net loss: US$11.8m (loss widened US$11.2m from FY 2020). Revenue exceeded analyst estimates by 1.8%. Over the next year, revenue is forecast to grow 14%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 46% per year whereas the company’s share price has fallen by 43% per year.お知らせ • Feb 24Tactile Systems Technology, Inc. Provides Revenue Guidance for the Full Year 2022Tactile Systems Technology, Inc. provided revenue guidance for the full year 2022. For the year, the company expected total revenue in the range of $235.0 million to $240.0 million, representing growth of approximately 13% to 15% year-over-year, compared to total revenue of $208.1 million in 2021.お知らせ • Feb 19Tactile Systems Technology, Inc. Announces Qui Tam Lawsuit Dropped by PlaintiffTactile Systems Technology, Inc. announced that the qui tam lawsuit filed by a competitor has been dropped and dismissed by a federal judge in Texas. The lawsuit challenged the propriety of Tactile Medical’s patient and physician education programs. This dismissal validates Tactile Medical’s longstanding confidence in the validity of its programs. Tactile Medical will not pay any damages, penalties, attorney fees or other compensation. With the claims dismissed by the federal judge, Tactile Medical also dismissed its remaining counterclaims. Tactile Medical will look forward to continuing to serve its patients through an industry-leading research and development and a comprehensive patient training program. Tactile Medical is committed to increasing awareness of lymphatic and vascular conditions through support of research and high-quality medical education, partnering with healthcare professionals, and most importantly, serving patients with dignity and care.お知らせ • Jan 28Tactile Systems Technology, Inc. to Report Q4, 2021 Results on Feb 22, 2022Tactile Systems Technology, Inc. announced that they will report Q4, 2021 results After-Market on Feb 22, 2022Valuation Update With 7 Day Price Move • Dec 09Investor sentiment improved over the past weekAfter last week's 16% share price gain to €19.30, the stock trades at a forward P/E ratio of 122x. Average forward P/E is 39x in the Medical Equipment industry in Germany. Total loss to shareholders of 58% over the past three years.Valuation Update With 7 Day Price Move • Nov 15Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to €25.60, the stock trades at a forward P/E ratio of 171x. Average forward P/E is 39x in the Medical Equipment industry in Germany. Total loss to shareholders of 48% over the past three years.Reported Earnings • Nov 09Third quarter 2021 earnings released: US$0.17 loss per share (vs US$0.13 profit in 3Q 2020)The company reported a soft third quarter result with weaker earnings and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: US$52.5m (up 6.9% from 3Q 2020). Net loss: US$3.36m (down 238% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.お知らせ • Sep 10Tactile Systems Technology, Inc. (NasdaqGM:TCMD) acquired Substantially All of the Assets of AffloVest for $100 million.Tactile Systems Technology, Inc. (NasdaqGM:TCMD) acquired Substantially All of the Assets of AffloVest for $100 million on September 8, 2021. Tactile Systems Technology, Inc. (NasdaqGM:TCMD) will pay consideration of $80 million in cash, of which a total of $0.5 million was deposited into escrow accounts at closing for purposes of satisfying certain post-closing purchase price adjustments and indemnification claims, if needed. The International Biophysics Corporation may receive earn out payments of $20 million on the basis of certain revenue targets,$10 million based on revenues of the AffloVest during the 12 month period beginning on the first day of the calendar month following the closing, and up to $10.0 million based on revenues during the 12-month period thereafter. The transaction is financed through a combination of cash on hand and $55 million of borrowings under its existing credit facility, which is being amended in connection with this transaction. The acquisition is expected to be accretive to the Company’s adjusted EBITDA, excluding purchase accounting, non-cash amortization and transaction costs, by the end of year one post-closing. C. Walker Brierre of Holland & Knight LLP acted as a legal advisor to International Biophysics Corporation and Jonathan Zimmerman of Faegre Drinker Biddle & Reath LLP acted as a legal advisor to Tactile Systems Technology, Inc. (NasdaqGM:TCMD). Tactile Systems Technology, Inc. (NasdaqGM:TCMD) completed the acquisition of Substantially All of the Assets of AffloVest on September 8, 2021.お知らせ • Aug 05Tactile Systems Technology, Inc. Revises Revenue Guidance for the Full Year 2021Tactile Systems Technology, Inc. revised revenue guidance for the full year 2021. The company now expected full year 2021 total revenue in the range of $216.3 million to $224.5 million, representing growth of approximately 16% to 20% year-over-year, compared to total revenue of $187.1 million in 2020. The company’s prior 2021 revenue guidance expectations called for total revenue in the range of $215.3 million to $224.5 million, representing an increase of 15% to 20%.Reported Earnings • Aug 03Second quarter 2021 earnings released: EPS US$0.066 (vs US$0.72 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$51.1m (up 45% from 2Q 2020). Net income: US$1.31m (up US$15.2m from 2Q 2020). Profit margin: 2.6% (up from net loss in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has remained flat, which means it is well ahead of earnings.Recent Insider Transactions • Jul 08President recently sold €125k worth of stockOn the 7th of July, Daniel Reuvers sold around 3k shares on-market at roughly €42.19 per share. This was the largest sale by an insider in the last 3 months. This was Daniel's only on-market trade for the last 12 months.業績と収益の成長予測DB:3L3 - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202843350N/AN/A112/31/202739733N/AN/A512/31/202636225N/AN/A56/30/2026350252431N/A3/31/2026344203942N/A12/31/2025330194043N/A9/30/2025312183942N/A6/30/2025299153942N/A3/31/2025293163840N/A12/31/2024293173841N/A9/30/2024285154043N/A6/30/2024282333437N/A3/31/2024277283537N/A12/31/2023274293336N/A9/30/2023271252021N/A6/30/202326601720N/A3/31/2023258-468N/A12/31/2022247-1835N/A9/30/2022235-3047N/A6/30/2022222-3124N/A3/31/2022213-25-20N/A12/31/2021208-1203N/A9/30/2021206802N/A6/30/20212021479N/A3/31/2021186-2-11N/A12/31/2020187-113N/A9/30/2020185-8-5-2N/A6/30/2020185-8-11-6N/A3/31/20201968N/A2N/A12/31/201918911N/A3N/A9/30/20191799N/A8N/A6/30/20191668N/A11N/A3/31/20191558N/A12N/A12/31/20181447N/A9N/A9/30/20181326N/A8N/A6/30/20181246N/A6N/A3/31/20181167N/A2N/A12/31/20171096N/A4N/A9/30/20171036N/A3N/A6/30/2017975N/A3N/A3/31/2017912N/A8N/A12/31/2016852N/A7N/A9/30/2016770N/A7N/A6/30/2016710N/A4N/A3/31/201666-1N/A2N/A12/31/2015630N/A2N/A9/30/2015600N/A1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 3L3の予測収益成長率 (年間24.1% ) は 貯蓄率 ( 2.1% ) を上回っています。収益対市場: 3L3の収益 ( 24.1% ) はGerman市場 ( 15.3% ) よりも速いペースで成長すると予測されています。高成長収益: 3L3の収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: 3L3の収益 ( 8.4% ) German市場 ( 6.7% ) よりも速いペースで成長すると予測されています。高い収益成長: 3L3の収益 ( 8.4% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 3L3の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/18 10:37終値2026/08/18 00:00収益2026/06/30年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Tactile Systems Technology, Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。12 アナリスト機関null nullArgus Research CompanyKyle BauserB. Riley Securities, Inc.Anderson SchockB. Riley Securities, Inc.9 その他のアナリストを表示
お知らせ • Aug 11Tactile Systems Technology, Inc. Updates Earnings Guidance for the Full Year of 2026Tactile Systems Technology, Inc. updated earnings guidance for the full year of 2026. For the year, the company expects total revenue in the range of $360 million to $366 million, representing growth of approximately 9% to 11% year-over-year.
お知らせ • May 07Tactile Systems Technology, Inc. Updates Earnings Guidance for the Full Year Ending December 31, 2026Tactile Systems Technology, Inc. updated earnings guidance for the full year ending December 31, 2026. For the period, the company expects total revenue in the range of $360 million to $368 million, representing growth of approximately 9% to 12% year-over-year, compared to total revenue of $329.5 million in 2025. The Company’s prior 2026 guidance expectation was total revenue in the range of $357 million to $365 million, representing growth of approximately 8% to 11% year-over-year. Net income in the range of $24,697,000 to $26,137,000.
お知らせ • Feb 18+ 1 more updateTactile Systems Technology, Inc. Provides Earnings Guidance for the Full Year Ending December 31, 2026Tactile Systems Technology, Inc. provided earnings guidance for the full year ended December 31, 2026. The company expects full year 2026 total revenue in the range of $357 million to $365 million, representing growth of approximately 8% to 11% year-over-year, compared to total revenue of $329.5 million in 2025. The company expects Net income to be in the range of $26,080,000 to $27,519,000.
お知らせ • Nov 05Tactile Systems Technology, Inc. Updates Earning Guidance for the Full Year 2025Tactile Systems Technology, Inc. updated earning guidance for the full year 2025. For the period, the total revenue in the range of $317 million to $321 million, representing growth of approximately 8% to 10% year-over-year, compared to total revenue of $293.0 million in 2024. The Company’s prior 2025 guidance expectation was total revenue in the range of $310 million to $315 million, representing growth of approximately 6% to 8% year-over-year.
お知らせ • Aug 07Tactile Systems Technology, Inc. Updates Earnings Guidance for the Full Year 2025Tactile Systems Technology, Inc. updated earnings guidance for the full year 2025. For the period, Company now expects total revenue in the range of $310 million to $315 million, representing growth of approximately 6% to 8% year-over-year, compared to total revenue of $293.0 million in 2024. The Company’s prior 2025 guidance expectation was total revenue in the range of $309 million to $315 million, representing growth of approximately 5% to 8% year-over-year.
お知らせ • May 07Tactile Systems Technology, Inc. Updates Financial Guidance for Full Year Ending December 31, 2025Tactile Systems Technology, Inc. updated financial guidance for full year ending December 31, 2025. For the period, the company expects total revenue in the range of $309 million to $315 million representing growth of approximately 5% to 8% year-over-year, compared to total revenue of $293.0 million in 2024. The Company’s prior 2025 guidance expectation was total revenue in the range of $316 million to $322 million, representing growth of approximately 8% to 10% year-over-year. The company expects Net income to be in the range of $13,400,000 to $14,800,000.
Valuation Update With 7 Day Price Move • Aug 17Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to €20.38, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 17x in the Medical Equipment industry in Germany. Total returns to shareholders of 24% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €19.96 per share.
Recent Insider Transactions • Aug 13CEO, President & Director recently sold €280k worth of stockOn the 10th of August, Sheri Dodd sold around 11k shares on-market at roughly €25.49 per share. This transaction amounted to 11% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Sheri has been a net seller over the last 12 months, reducing personal holdings by €915k.
Reported Earnings • Aug 11Second quarter 2026 earnings released: EPS: US$0.34 (vs US$0.14 in 2Q 2025)Second quarter 2026 results: EPS: US$0.34 (up from US$0.14 in 2Q 2025). Revenue: US$85.7m (up 8.6% from 2Q 2025). Net income: US$7.79m (up 142% from 2Q 2025). Profit margin: 9.1% (up from 4.1% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 10% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Aug 11Tactile Systems Technology, Inc. Updates Earnings Guidance for the Full Year of 2026Tactile Systems Technology, Inc. updated earnings guidance for the full year of 2026. For the year, the company expects total revenue in the range of $360 million to $366 million, representing growth of approximately 9% to 11% year-over-year.
お知らせ • Jul 23Tactile Systems Technology, Inc. to Report Q2, 2026 Results on Aug 10, 2026Tactile Systems Technology, Inc. announced that they will report Q2, 2026 results After-Market on Aug 10, 2026
Valuation Update With 7 Day Price Move • Jun 29Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €26.56, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 17x in the Medical Equipment industry in Germany. Total returns to shareholders of 19% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €40.69 per share.
お知らせ • Jun 29Tactile Systems Technology, Inc.(NasdaqGM:TCMD) dropped from Russell 2000 Defensive IndexTactile Systems Technology, Inc.(NasdaqGM:TCMD) dropped from Russell 2000 Defensive Index
お知らせ • Jun 03Tactile Systems Technology Announces Full Commercial Launch of Next-Generation Afflovest High-Frequency Chest Wall Oscillation Therapy SystemTactile Systems Technology announced full commercial launch of its next-generation AffloVest high-frequency chest wall oscillation (HFCWO) therapy system. The next-generation system maintains its indication for use as a treatment option for chronic neuromuscular and respiratory conditions, including cystic fibrosis and bronchiectasis, across pediatric and geriatric populations, while introducing enhancements to patient comfort, ease of use, and connected care capabilities to support long-term therapy adherence. Effective management of chronic respiratory conditions requires a multimodal approach in which airway clearance plays a critical, complementary role alongside other therapies, including pharmacological agents. While these medications target inflammation and infection, they do not directly address retained mucus, one of the primary drivers of impaired lung function and disease progression. HFCWO therapy, including AffloVest, mechanically mobilizes and facilitates removal of secretions to improve ventilation and support overall respiratory health, and published clinical literature demonstrates its ability to enhance mucus transport and reduce secretion burden. Based on feedback from patients, clinicians, and durable medical equipment (DME) partners, the next-generation AffloVest was intentionally designed with a focus on simplifying setup and improving the overall treatment experience. The new system features a lighter and more adjustable vest than its predecessor to accommodate a broad range of patient ages and body types. Paired with a redesigned controller built for intuitive navigation, AffloVest is now easier to put on, simpler to operate, and more comfortable to wear at home and on the go. The next-generation AffloVest also offers built-in Wi-Fi and Bluetooth connectivity, enabling patients to visualize their treatment progress and stay engaged with therapy, while equipping clinicians with real-world data needed to have more informed, personalized treatment discussions. DME providers also gain access to therapy utilization data that supports patient care and reimbursement requirements with payers.
お知らせ • May 07Tactile Systems Technology, Inc. Updates Earnings Guidance for the Full Year Ending December 31, 2026Tactile Systems Technology, Inc. updated earnings guidance for the full year ending December 31, 2026. For the period, the company expects total revenue in the range of $360 million to $368 million, representing growth of approximately 9% to 12% year-over-year, compared to total revenue of $329.5 million in 2025. The Company’s prior 2026 guidance expectation was total revenue in the range of $357 million to $365 million, representing growth of approximately 8% to 11% year-over-year. Net income in the range of $24,697,000 to $26,137,000.
お知らせ • Apr 21Tactile Systems Technology, Inc. to Report Q1, 2026 Results on May 04, 2026Tactile Systems Technology, Inc. announced that they will report Q1, 2026 results After-Market on May 04, 2026
お知らせ • Mar 10Tactile Systems Technology, Inc. Announces Appointment of Andrea A. Pearson to Board of Directors and Member of the Compliance and Reimbursement Committee and of the Nominating and Corporate Governance Committee, Effective March 9, 2026On March 4, 2026, the board of directors of Tactile Systems Technology, Inc. announced the appointment of Andrea Pearson to the Company’s Board of Directors (“Board”) and as a member of the Compliance & Reimbursement and Nominating & Corporate Governance Committees, effective March 9, 2026. Ms. Pearson is an accomplished senior executive and growth strategist with deep expertise in scaling healthcare organizations. Her extensive experience spans more than 25 years and includes exposure to product development, customer acquisition, branding, marketing communications, and public relations. Most recently, she served as Growth Advisor and Chief Marketing Officer at Harbor Health, a healthcare organization that integrates clinical care with health insurance coverage. Previously, she was Chief Growth Officer, and, before that, Chief Marketing Officer at DispatchHealth, a leader in at-home, hospital-level care, where she architected the company’s growth strategy, scaling the business from two to more than 50 U.S. markets while driving a 30x increase in revenue. Prior to DispatchHealth, Ms. Pearson held multiple executive roles at HealthGrades, a leading online platform connecting patients with healthcare providers, including Chief Marketing Officer and Executive Vice President and General Manager. As Chief Marketing Officer, she grew the consumer audience from one million monthly to one million daily visitors. Her earlier career experience includes 10 years of increasing responsibility across product development, marketing, and general management roles.
お知らせ • Feb 19Tactile Systems Technology, Inc., Annual General Meeting, May 06, 2026Tactile Systems Technology, Inc., Annual General Meeting, May 06, 2026.
お知らせ • Feb 18+ 1 more updateTactile Systems Technology, Inc. Provides Earnings Guidance for the Full Year Ending December 31, 2026Tactile Systems Technology, Inc. provided earnings guidance for the full year ended December 31, 2026. The company expects full year 2026 total revenue in the range of $357 million to $365 million, representing growth of approximately 8% to 11% year-over-year, compared to total revenue of $329.5 million in 2025. The company expects Net income to be in the range of $26,080,000 to $27,519,000.
お知らせ • Feb 04Tactile Systems Technology, Inc. to Report Q4, 2025 Results on Feb 17, 2026Tactile Systems Technology, Inc. announced that they will report Q4, 2025 results at 4:00 PM, US Eastern Standard Time on Feb 17, 2026
お知らせ • Nov 05Tactile Systems Technology, Inc. Updates Earning Guidance for the Full Year 2025Tactile Systems Technology, Inc. updated earning guidance for the full year 2025. For the period, the total revenue in the range of $317 million to $321 million, representing growth of approximately 8% to 10% year-over-year, compared to total revenue of $293.0 million in 2024. The Company’s prior 2025 guidance expectation was total revenue in the range of $310 million to $315 million, representing growth of approximately 6% to 8% year-over-year.
お知らせ • Nov 04Tactile Systems Technology, Inc. (NasdaqGM:TCMD) announces an Equity Buyback for $25 million worth of its shares.Tactile Systems Technology, Inc. (NasdaqGM:TCMD) announces an share repurchase program. Under the program, the company will repurchase up to $25 million worth of its common stock. The program will be financed via existing cash and future cash flows. The repurchase program is valid till November 3, 2027.
お知らせ • Oct 30Tactile Systems Technology, Inc. Announces the Presentation of New Six-Month Clinical DataTactile Systems Technology, Inc. announced the presentation of new six-month clinical data during the late-breaking poster session at the American Congress of Rehabilitation Medicine (ACRM) 102nd Annual Fall Conference demonstrating sustained clinical benefits of Flexitouch®? Plus as a first-line therapy for treating patients with head and neck cancer-related lymphedema. The six-month analysis, drawn from a large randomized controlled trial, showed improvement in lymphedema symptom burden for participants in both the advanced pneumatic compression device (APCD) study arm, consisting of treatment with Flexitouch Plus, and the usual care study arm, which included therapist-guided multimodal treatment. Symptom severity was based on scoring from disease-specific patient-reported symptom surveys. Welling improvements were also observed in objective clinical assessments, including CT imaging. Highlights from the six-month results include: Flexitouch Plus demonstrated reduced internal swelling at the majority of anatomical sites (13 of 19), with statistically significant improvement achieved in the base of tongue (p=0.008) and arytenoids (p=0.023); Clinician-reported outcome measures of both internal (Endoscopy Modified Patterson Scale) and external soft tissue swelling favored Flexitouch Plus over usual care; Significant improvement in epiglottic thickness and prevertebral soft tissue thickness at C3 in both groups at six months; The initial patient benefit of Flexitouch Plus and usual care was maintained over the six-month study timeframe; and Both groups demonstrated sustained improvement in symptom burden over the six-month study period. The new long-term results follow two-month data released at ASCO in June 2025 and are drawn from the largest prospective, randomized controlled study ever conducted among head and neck cancer survivors in the United States, which enrolled 236 patients across 10 academic and community-based centers. The sustained patient benefits associated with Flexitouch Plus, as demonstrated in the six-month results, combined with the early improvements seen at two months, are clinically important for head and neck lymphedema patients and the providers who treat them. Not only is therapist-guided care limited in the U.S., but payer coverage policies have restricted access to Flexitouch Plus in this population.
お知らせ • Oct 21Tactile Systems Technology, Inc. to Report Q3, 2025 Results on Nov 03, 2025Tactile Systems Technology, Inc. announced that they will report Q3, 2025 results After-Market on Nov 03, 2025
お知らせ • Aug 07Tactile Systems Technology, Inc. Updates Earnings Guidance for the Full Year 2025Tactile Systems Technology, Inc. updated earnings guidance for the full year 2025. For the period, Company now expects total revenue in the range of $310 million to $315 million, representing growth of approximately 6% to 8% year-over-year, compared to total revenue of $293.0 million in 2024. The Company’s prior 2025 guidance expectation was total revenue in the range of $309 million to $315 million, representing growth of approximately 5% to 8% year-over-year.
お知らせ • Jul 22Tactile Systems Technology, Inc. to Report Q2, 2025 Results on Aug 04, 2025Tactile Systems Technology, Inc. announced that they will report Q2, 2025 results After-Market on Aug 04, 2025
お知らせ • Jun 04Tactile Systems Technology, Inc. Announces the Presentation of New Clinical Data at the American Society of Clinical Oncology 2025 Annual MeetingTactile Systems Technology, Inc. announced the presentation of new clinical data at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting that demonstrates significant clinical and quality-of-life benefits associated with use of the Company's Flexitouch Plus versus usual care in treating patients with head and neck cancer-related lymphedema. The two-month analysis featured data from the Company's six-month clinical trial, which examines the effectiveness of Flexitouch Plus, an advanced pneumatic compression device (APCD), versus usual care in treating head and neck cancer survivors. The study includes 236 subjects across 10 academic and community sites, representing the largest prospective, randomized controlled study on this patient group ever conducted in the United States. Outcome measures include changes in disease-specific patient-reported symptom survey scores and objective clinical assessments, including CT imaging. Two-month data demonstrated that usual care and APCD are similarly effective treatment modalities for head and neck lymphedema. Specific areas of differentiation showed: Usual care participants took an average of 29.8 days to begin therapist guided lymphedema treatment (TGLT), while APCD participants received their device in 17.9 days; Of participants randomized to usual care, only 71% received TGLT compared to 94.9% of those in the APCD group; APCD participants had significant reduction in swelling via digital photography and total Head and Neck Cancer Related Lymphedema and Fibrosis Grading (HN-LEFG) scores while usual care participants exhibited incremental improvements; and Self-reported symptom improvement occurred in both groups, with APCD demonstrating significant improvement on three of the six health-related quality-of-life sub scales. Flexitouch Plus is an FDA-cleared therapy designed for at-home treatment of lymphedema, chronic venous insufficiency (CVI), and chronic wounds.
お知らせ • May 07Tactile Systems Technology, Inc. Updates Financial Guidance for Full Year Ending December 31, 2025Tactile Systems Technology, Inc. updated financial guidance for full year ending December 31, 2025. For the period, the company expects total revenue in the range of $309 million to $315 million representing growth of approximately 5% to 8% year-over-year, compared to total revenue of $293.0 million in 2024. The Company’s prior 2025 guidance expectation was total revenue in the range of $316 million to $322 million, representing growth of approximately 8% to 10% year-over-year. The company expects Net income to be in the range of $13,400,000 to $14,800,000.
お知らせ • Apr 22Tactile Systems Technology, Inc. to Report Q1, 2025 Results on May 05, 2025Tactile Systems Technology, Inc. announced that they will report Q1, 2025 results After-Market on May 05, 2025
お知らせ • Mar 31Tactile Systems Technology, Inc., Annual General Meeting, May 07, 2025Tactile Systems Technology, Inc., Annual General Meeting, May 07, 2025. Location: wells fargo center, suite 2200, 90 south seventh st, minnesota 55402., minneapolis United States
お知らせ • Feb 19Tactile Systems Technology, Inc. Provides Earnings Guidance for the Year Ending December 31, 2025Tactile Systems Technology, Inc. provided earnings guidance for the year ending December 31, 2025. The Company expects full year 2025 total revenue in the range of $316 million to $322 million, representing growth of approximately 8% to 10% year-over-year, compared to total revenue of $293.0 million in 2024. The company expects Net income to be in the range of $15,750,000 to $17,150,000.
お知らせ • Feb 06Tactile Systems Technology, Inc. to Report Q4, 2024 Results on Feb 18, 2025Tactile Systems Technology, Inc. announced that they will report Q4, 2024 results After-Market on Feb 18, 2025
お知らせ • Feb 04Tactile Medical Expands Launch of Nimbl to Include Patients with Lower Extremity LymphedemaTactile Systems Technology, Inc. announced that Nimbl, its next-generation pneumatic compression platform, is now commercially available throughout the United States (U.S.) for the treatment of both upper and lower extremity lymphedema. Nimbl's expanded availability to include lower extremity conditions ("phlebolymphedema") follows its commercial introduction in October 2024, initially focused on treating patients suffering from upper extremity lymphedema". Nimbl is the smallest pneumatic compression device (PCD) of its kind, featuring a compact controller that is 68% lighter and 40% smaller than the Company's current generation PCD. The lower extremity garment uses 94% lessosing, making the device easy to transport and manage. Nimbl is the only basic PCD with Bluetooth®? connectivity, providing patients a way to track their treatments and symptom progress with the Company's free Kylee™? digital application.
お知らせ • Jan 13Tactile Systems Technology, Inc. Announces the Appointment of Laura King to the Board of Directors and as A Member of the Audit and Compliance & Reimbursement CommitteesTactile Systems Technology, Inc. announced the appointment of Laura King to the Company’s Board of Directors (“Board”) and as a member of the Audit and Compliance & Reimbursement Committees, effective January 13, 2025. Ms. King is a seasoned healthcare executive with a proven track record of leadership and developing innovative products that enhance patient care. Her extensive experience includes a 22-year career at General Electric Company (GE), where she served as a Company Officer in her role as President & CEO of GE Healthcare’s Global Interventional Business, which provided clinical solutions enabling minimally invasive procedures in cardiology, interventional radiology, and surgery. Her earlier experience at GE included various senior level audit and finance roles, including Chief Information Officer & Chief Financial Officer, Consumer & ECM Motors. Ms. King is currently co-founder & CEO of BiaCure, Inc., a developer of effective treatments for nail fungus. Previously, she co-founded and served as CEO of Elucent Medical, a developer of a real-time surgical navigation platform that has positively impacted over 10,000 breast cancer patients. Ms. King also served as President & CEO of NeuWave Medical, a manufacturer and marketer of a minimally invasive soft tissue microwave ablation system to destroy tumor cells, which was acquired by Johnson & Johnson’s MedTech division.
Valuation Update With 7 Day Price Move • Nov 13Investor sentiment improves as stock rises 20%After last week's 20% share price gain to €14.70, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 23x in the Medical Equipment industry in Germany. Total loss to shareholders of 41% over the past three years.
New Risk • Nov 06New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 5.4% Last year net profit margin: 9.2% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (5.4% net profit margin). Shareholders have been diluted in the past year (2.3% increase in shares outstanding).
お知らせ • Nov 06Tactile Systems Technology, Inc. (NasdaqGM:TCMD) announces an Equity Buyback for $30 million worth of its shares.Tactile Systems Technology, Inc. (NasdaqGM:TCMD) announces an share repurchase program. Under the program, the company will repurchase up to $30 million worth of its common stock. The program will be financed via existing cash and cash equivalents and future cash flows. The repurchase program is valid till October 31, 2026.
お知らせ • Nov 05Tactile Systems Technology, Inc. Revises Revenue Guidance for the Year 2024Tactile Systems Technology, Inc. revised revenue guidance for the year 2024. The Company is updating its 2024 financial outlook and now expects full year 2024 total revenue in the range of $292 million to $295 million, representing growth of approximately 6% to 8% year-over-year, compared to total revenue of $274.4 million in 2023. The Company’s prior 2024 guidance expectation was total revenue in the range of $293 million to $298 million, representing growth of approximately 7% to 9%.
お知らせ • Oct 22Tactile Systems Technology, Inc. to Report Q3, 2024 Results on Nov 04, 2024Tactile Systems Technology, Inc. announced that they will report Q3, 2024 results After-Market on Nov 04, 2024
お知らせ • Oct 02Tactile Systems Technology, Inc. Launches Next-Generation Nimbl™ Lymphedema PlatformTactile Systems Technology, Inc. announced that Nimbl, its next-generation pneumatic compression platform, is now commercially available throughout the United States for the treatment of upper extremity lymphedema. Nimbl, which is significantly smaller and lighter than previous device iterations, is indicated as a treatment option for patients with both upper and lower extremity lymphedema, chronic edema, venous insufficiency, and wound healing. Nimbl received U.S Food & Drug Administration (FDA) 510(k) clearance in June 2024 and Pricing, Data Analysis, and Coding (PDAC) approval from the Centers for Medicare & Medicaid Services (CMS) in September 2024. The Company expects to make Nimbl commercially available for patients with lower extremity conditions in the coming months. Nimbl is 68% lighter, 40% smaller, and uses 33% less hosing than the Company’s current generation basic pneumatic compression device (PCD). Its compact design is the smallest PCD of its kind, making it an ideal therapy for daily use at home or on the go. In addition to the patient centric feature enhancements, Nimbl also offers connectivity to the Company’s free Kylee™ digital application, providing patients a simple way to track their usage and change in symptoms, and to share results with their care team. Convenient accessories are available for purchase including a rechargeable battery and custom-designed travel bag.
New Risk • Sep 26New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 1.2% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 1.2% per year for the foreseeable future. Minor Risk Shareholders have been diluted in the past year (2.2% increase in shares outstanding).
お知らせ • Sep 16Tactile Medical Receives PDAC Approval for Nimbl Lymphedema PlatformTactile Systems Technology, Inc. announced that the Pricing, Data Analysis, and Coding (PDAC) contractor for the Centers for Medicare & Medicaid Services (CMS) has approved the use of Healthcare Common Procedure Coding System (HCPCS) code E0651 for billing the Durable Medical Equipment Medicare Administrative Contractors for Nimbl, the Company’s next-generation pneumatic compression platform. PDAC approval is subsequent to the receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) in June 2024. The Company will make Nimbl commercially available in the United States in the coming weeks. Nimbl is the next generation of the Company’s basic lymphedema compression solution and is indicated for the treatment of lymphedema, chronic edema, venous insufficiency, and wound healing. The device features several key patient-friendly enhancements over prior generations, including a 40% and 68% reduction in size and weight, respectively, making it more portable and ideal for active lifestyles. Nimbl offers connectivity to the Company’s Kylee digital application, enabling patients to actively track their therapy progress and share results with their care team.
New Risk • Aug 15New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: €57k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (2.2% increase in shares outstanding). Significant insider selling over the past 3 months (€57k sold).
Reported Earnings • Aug 06Second quarter 2024 earnings released: EPS: US$0.18 (vs US$0.004 loss in 2Q 2023)Second quarter 2024 results: EPS: US$0.18 (up from US$0.004 loss in 2Q 2023). Revenue: US$73.2m (up 7.1% from 2Q 2023). Net income: US$4.30m (up US$4.40m from 2Q 2023). Profit margin: 5.9% (up from net loss in 2Q 2023). Revenue is forecast to grow 10.0% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.
お知らせ • Aug 06+ 1 more updateTactile Systems Technology, Inc. Revises Financial Guidance for the Full Year 2024Tactile Systems Technology, Inc. revised financial guidance for the full year 2024. The Company is updating its 2024 financial outlook and now expects full year 2024 total revenue in the range of $293 million to $298 million, representing growth of approximately 7% to 9% year-over-year, compared to total revenue of $274.4 million in 2023. The Company’s prior 2024 guidance expectation was total revenue in the range of $300 million to $305 million, representing growth of approximately 9% to 11%.
お知らせ • Jul 23Tactile Systems Technology, Inc. to Report Q2, 2024 Results on Aug 05, 2024Tactile Systems Technology, Inc. announced that they will report Q2, 2024 results After-Market on Aug 05, 2024
New Risk • May 07New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 21% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (2.3% increase in shares outstanding).
Reported Earnings • May 07First quarter 2024 earnings released: US$0.093 loss per share (vs US$0.089 loss in 1Q 2023)First quarter 2024 results: US$0.093 loss per share (further deteriorated from US$0.089 loss in 1Q 2023). Revenue: US$61.1m (up 3.8% from 1Q 2023). Net loss: US$2.21m (loss widened 17% from 1Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.
お知らせ • Apr 24+ 1 more updateTactile Systems Technology, Inc. Provides Preliminary Revenue Guidance for the First Quarter 2024Tactile Systems Technology, Inc. provided preliminary revenue guidance for the first quarter 2024. Unaudited total revenue for the first quarter of 2024 is expected to be approximately $61 million, compared to $58.8 million in the first quarter of 2023.
お知らせ • Apr 16Tactile Systems Technology, Inc. to Report Q1, 2024 Results on May 06, 2024Tactile Systems Technology, Inc. announced that they will report Q1, 2024 results After-Market on May 06, 2024
お知らせ • Mar 28Tactile Systems Technology, Inc., Annual General Meeting, May 08, 2024Tactile Systems Technology, Inc., Annual General Meeting, May 08, 2024, at 09:00 Central Daylight. Location: Wells Fargo Center 90 South Seventh St., Ste 2200 Mineapolis Minnesota United States Agenda: To elect eight directors; to ratify the appointment of Grant Thornton LLP as our independent registered public accounting firm for the year ending December 31, 2024; to approve, on an advisory basis, the 2023 compensation of our named executive officers as disclosed in the accompanying Proxy Statement; to approve an amendment to our Amended and Restated Certificate of Incorporation to allow for exculpation of officers as permitted by Delaware law; and to transact such other business as may properly come before the meeting or at any and all adjournments or postponements thereof.
Reported Earnings • Feb 21Full year 2023 earnings released: EPS: US$1.24 (vs US$0.89 loss in FY 2022)Full year 2023 results: EPS: US$1.24 (up from US$0.89 loss in FY 2022). Revenue: US$274.4m (up 11% from FY 2022). Net income: US$28.5m (up US$46.4m from FY 2022). Profit margin: 10% (up from net loss in FY 2022). The move to profitability was primarily driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.
お知らせ • Feb 20Tactile Systems Technology, Inc. Provides Revenue Guidance for the Full Year 2024Tactile Systems Technology, Inc. provided revenue guidance for the full year 2024. For the year, the company expected total revenue in the range of $300.0 million to $305.0 million, representing growth of approximately 9% to 11% year-over-year, compared to total revenue of $274.4 million in 2023.
お知らせ • Jan 30Tactile Systems Technology, Inc. to Report Q4, 2023 Results on Feb 20, 2024Tactile Systems Technology, Inc. announced that they will report Q4, 2023 results Pre-Market on Feb 20, 2024
Valuation Update With 7 Day Price Move • Nov 27Investor sentiment improves as stock rises 22%After last week's 22% share price gain to €12.60, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 24x in the Medical Equipment industry in Germany. Total loss to shareholders of 64% over the past three years.
Valuation Update With 7 Day Price Move • Nov 13Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to €9.80, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 24x in the Medical Equipment industry in Germany. Total loss to shareholders of 73% over the past three years.
New Risk • Nov 07New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 6.3% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings are forecast to decline by an average of 6.3% per year for the foreseeable future. Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (17% increase in shares outstanding).
Reported Earnings • Nov 07Third quarter 2023 earnings released: EPS: US$0.95 (vs US$0.11 loss in 3Q 2022)Third quarter 2023 results: EPS: US$0.95 (up from US$0.11 loss in 3Q 2022). Revenue: US$69.6m (up 6.6% from 3Q 2022). Net income: US$22.3m (up US$24.6m from 3Q 2022). Profit margin: 32% (up from net loss in 3Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 27% per year, which means it is performing significantly worse than earnings.
お知らせ • Nov 07Tactile Systems Technology, Inc. Updates Earnings Guidance for the Full Year 2023Tactile Systems Technology, Inc. updated earnings guidance for the full year 2023. For the period, the Company expects full year 2023 total revenue in the range of $273.0 million to $277.0 million, representing growth of approximately 11% to 12% year-over-year. The Company’s prior 2023 revenue guidance expectation was total revenue in the range of $274.0 million to $278.0 million, representing growth of approximately 11% to 13% year-over-year.
New Risk • Nov 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 8.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.9% average weekly change). Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (17% increase in shares outstanding).
お知らせ • Oct 05Tactile Systems Technology, Inc. to Report Q3, 2023 Results on Nov 06, 2023Tactile Systems Technology, Inc. announced that they will report Q3, 2023 results After-Market on Nov 06, 2023
お知らせ • Aug 09Tactile Systems Technology, Inc. Revises Earnings Guidance for the Full Year 2023Tactile Systems Technology, Inc. revised earnings guidance for the full year 2023. For the year, the company expects total revenue in the range of $274 million to $278 million, representing growth of approximately 11% to 13% year-over-year. The Company's prior 2023 revenue guidance expectations called for total revenue in the range of $271 million to $275 million, representing growth of approximately 10% to 11.5% year-over-year.
Reported Earnings • Aug 08Second quarter 2023 earnings released: US$0.004 loss per share (vs US$0.23 loss in 2Q 2022)Second quarter 2023 results: US$0.004 loss per share (improved from US$0.23 loss in 2Q 2022). Revenue: US$68.3m (up 15% from 2Q 2022). Net loss: US$100.0k (loss narrowed 98% from 2Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings.
お知らせ • Jul 21Tactile Systems Technology, Inc. Announces Senior Vice President of Sales ChangesTactile Systems Technology, Inc. announced the appointment of Sherri Ferstler to the position of Senior Vice President of Sales, effective July 31, 2023. Ms. Ferstler will succeed Eric Pauls, who will be resigning from the Company, effective July 28, 2023. Prior to joining Tactile Medical, Ms. Ferstler served as Vice President Sales, North America for Johnson & Johnson Vision since 2016. In this position, Ms. Ferstler led the field & inside sales teams, strategic accounts & training functions selling Acuvue brand contact lenses across multiple channels. Ms. Ferstler began her career in 1992 with Parke-Davis Pharmaceuticals where she served in a variety of sales, sales management and training and development roles. She joined Pfizer in 2000, serving as a district sales manager for all branded pharmaceutical products until 2003, then as Director of Division Operations and as a regional manager for Pfizer’s Urology and Respiratory product portfolios. From 2007 to 2016, Ms. Ferstler led regional and national sales teams for Endo Pharmaceuticals, Bayer Diabetes Care and Mylan Pharmaceuticals. Ms. Ferstler holds Bachelor of Arts in Psychology from the State University of New York College at Buffalo.
Buying Opportunity • Jul 07Now 22% undervaluedOver the last 90 days, the stock is up 37%. The fair value is estimated to be €27.12, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Meanwhile, the company became loss making.
お知らせ • Jun 30Tactile Systems Technology, Inc. to Report Q2, 2023 Results on Aug 07, 2023Tactile Systems Technology, Inc. announced that they will report Q2, 2023 results After-Market on Aug 07, 2023
お知らせ • Jun 25Tactile Systems Technology, Inc.(NasdaqGM:TCMD) dropped from Russell Small Cap Comp Value IndexTactile Systems Technology, Inc.(NasdaqGM:TCMD) dropped from Russell Small Cap Comp Value Index
Buying Opportunity • Jun 13Now 21% undervaluedOver the last 90 days, the stock is up 42%. The fair value is estimated to be €27.46, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Meanwhile, the company became loss making.
お知らせ • Jun 02Robbins Geller Rudman & Dowd LLP Announces Proposed Settlement in the Tactile Systems Technology, Inc. Securities LitigationRobbins Geller Rudman & Dowd LLP announced the following update regarding the Tactile Systems Technology, Inc. Securities Litigation: that a hearing will be held on August 23, 2023, (1) the proposed settlement (the “Settlement”) of the above-captioned action as set forth in the Stipulation of Settlement (“Stipulation”)1 for $5,000,000 in cash should be approved by the Court as fair, reasonable, and adequate; (2) the Judgment as provided under the Stipulation should be entered dismissing the Litigation with prejudice; (3) to award Lead Counsel attorneys’ fees and expenses out of the Settlement Fund (as defined in the Notice of Pendency and Proposed Settlement of Class Action (“Notice”), which is discussed below), and, if so, in what amounts; and (4) the Plan of Allocation should be approved by the Court as fair, reasonable, and adequate.
Reported Earnings • May 09First quarter 2023 earnings released: US$0.089 loss per share (vs US$0.78 loss in 1Q 2022)First quarter 2023 results: US$0.089 loss per share (improved from US$0.78 loss in 1Q 2022). Revenue: US$58.8m (up 23% from 1Q 2022). Net loss: US$1.89m (loss narrowed 88% from 1Q 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 29% per year, which means it has not declined as severely as earnings.
お知らせ • May 09Tactile Systems Technology, Inc. Provides Revenue Guidance for Full Year 2023Tactile Systems Technology, Inc. provided revenue guidance for the full year 2023. For the period, the company expects total revenue in the range of approximately $271.0 million to $275.0 million, representing growth of approximately 10% to 11.5% year-over-year. The Company’s prior 2023 revenue guidance expectations called for total revenue in the range of $269.0 million to $273.0 million, representing growth of approximately 9% to 11% year-over-year.
Recent Insider Transactions • Mar 05President recently sold €101k worth of stockOn the 28th of February, Daniel Reuvers sold around 7k shares on-market at roughly €14.32 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Daniel has been a net seller over the last 12 months, reducing personal holdings by €111k.
Breakeven Date Change • Feb 22Forecast breakeven date moved forward to 2023The 3 analysts covering Tactile Systems Technology previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of US$2.22m in 2023. Earnings growth of 148% is required to achieve expected profit on schedule.
Reported Earnings • Feb 22Full year 2022 earnings released: US$0.89 loss per share (vs US$0.60 loss in FY 2021)Full year 2022 results: US$0.89 loss per share (further deteriorated from US$0.60 loss in FY 2021). Revenue: US$246.8m (up 19% from FY 2021). Net loss: US$17.9m (loss widened 51% from FY 2021). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 49 percentage points per year, which is a significant difference in performance.
お知らせ • Feb 02Tactile Systems Technology, Inc. to Report Q4, 2022 Results on Feb 21, 2023Tactile Systems Technology, Inc. announced that they will report Q4, 2022 results Pre-Market on Feb 21, 2023
お知らせ • Jan 06Tactile Systems Technology, Inc. Appoints Carmen Volkart to Board of DirectorsTactile Systems Technology, Inc. announced the appointment of Carmen Volkart to the Company’s Board of Directors (“Board”), effective January 5, 2023. Since 2018, Carmen Volkart has served as the Chief Financial Officer of NatureWorks LLC, a privately-held advanced materials company and developer of renewably sourced polymers and chemicals. Prior to joining NatureWorks, she served as the Chief Financial Officer of NxThera, Inc., a privately-held medical device company focused on the treatment of benign prostatic hyperplasia, from 2012 until its acquisition by Boston Scientific in 2018. From 2010 to 2012, Ms. Volkart served as Chief Financial Officer of Tornier, N.V., a medical device company focused on treating musculoskeletal injuries and disorders of the shoulder, elbow, wrist, hand, ankle and foot. She led Tornier through a successful initial public offering in 2011. Prior to joining Tornier, Ms. Volkart served as Chief Operating and Financial Officer, Corporate Secretary, Compliance Officer and Treasurer of Spine Wave, Inc., a privately-held medical device company focused on minimally invasive spine surgery and expandable interbody devices, from 2006 to 2010. From 2004 to 2006, Ms. Volkart served as Executive Vice President, and Chief Financial Officer of American Medical Systems, Inc., a publicly traded medical device company focused on male and female pelvic health. Her career history also includes significant experience in various financial and managerial positions at both Medtronic, Inc., from 1992 to 2004, and Honeywell, Inc., from 1982 to 1992.
お知らせ • Nov 22Tactile Systems Technology, Inc. Reaches Agreement to Settle Securities Class Action LawsuitTactile Systems Technology, Inc. announced that it has entered into a Memorandum of Understanding to settle the previously disclosed securities class action lawsuit pending in the United States District Court for the District of Minnesota titled Mart v. Tactile Systems Technology, Inc. et al. The Company does not expect to fund any portion of the cash payments made in connection with the settlement. The settlement does not constitute an admission of any liability or wrongdoing by Tactile Medical or any of its current or former officers or directors. Nonetheless, it is desirable and beneficial to Tactile Medical and its stockholders to settle the lawsuit to avoid the costs, burden and distraction of continued litigation. The settlement framework provides for payment of a total of $5.0 million to settle claims brought on behalf of investors who purchased the Company’s common stock in the market between May 7, 2018 and June 8, 2020. The Company’s insurers are funding the settlement payment to Plaintiffs and have agreed to the terms of the MOU. The settlement is subject to the parties reaching agreement on various non-monetary terms, and court approval of the final terms will be required. The parties have agreed to negotiate in good faith to execute definitive stipulations of settlement and related documents to be filed with the court, which, among other things, will provide that upon final approval of the settlement by the court, the case will be dismissed with prejudice, with mutual releases by all parties.
Board Change • Nov 16High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 5 experienced directors. No highly experienced directors. Independent Chairman Bill Burke is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Nov 09Third quarter 2022 earnings released: US$0.11 loss per share (vs US$0.17 loss in 3Q 2021)Third quarter 2022 results: US$0.11 loss per share (improved from US$0.17 loss in 3Q 2021). Revenue: US$65.3m (up 24% from 3Q 2021). Net loss: US$2.28m (loss narrowed 32% from 3Q 2021). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 47 percentage points per year, which is a significant difference in performance.
お知らせ • Nov 08Tactile Systems Technology, Inc. Revises Earnings Guidance for the Year 2022Tactile Systems Technology, Inc. revised earnings guidance for the year 2022. The Company now expects full year 2022 total revenue in the range of $242.0 million to $245.0 million, representing growth of approximately 16% to 18% year-over-year, compared to total revenue of $208.1 million in 2021. The Company’s prior 2022 revenue guidance expectations called for total revenue in the range of $238.0 million to $242.0 million, representing growth of approximately 14% to 16% year-over-year.
お知らせ • Sep 27Tactile Systems Technology, Inc. to Report Q3, 2022 Results on Nov 07, 2022Tactile Systems Technology, Inc. announced that they will report Q3, 2022 results After-Market on Nov 07, 2022
Reported Earnings • Aug 02Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.066 profit in 2Q 2021)Second quarter 2022 results: US$0.23 loss per share (down from US$0.066 profit in 2Q 2021). Revenue: US$59.6m (up 17% from 2Q 2021). Net loss: US$4.64m (down 456% from profit in 2Q 2021). Over the next year, revenue is forecast to grow 15%, compared to a 7.3% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 42 percentage points per year, which is a significant difference in performance.
お知らせ • Aug 02Tactile Systems Technology, Inc. Raises Earnings Guidance for the Full Year 2022Tactile Systems Technology, Inc. raised earnings guidance for the full year 2022. For the year, the company expected total revenue in the range of $238.0 million to $242.0 million, representing growth of approximately 14% to 16% year-over-year, compared to total revenue of $208.1 million in 2021. The Company’s prior 2022 revenue guidance expectations called for total revenue in the range of $235.0 million to $240.0 million, representing growth of approximately 13% to 15% year-over-year.
お知らせ • Jul 26Tactile Medical Introduces New ComfortEase Flexitouch Plus Garments and Kylee Mobile ApplicationTactile Systems Technology, Inc. announced the full market release of its new ComfortEase™ garments, part of the Flexitouch® Plus system. In addition, Tactile Medical is putting the power of lymphedema health tracking in the palm of patients’ hands with the launch of its Kylee™ mobile application. Enhancing the Patient Experience with ComfortEase Leveraging over 18,000 points of feedback from patients and therapists, Tactile Medical redesigned the Flexitouch Plus garments to be easier to use, better fitting and more comfortable, all intended to improve patient experience and satisfaction. Together with the Flexitouch Plus controller, the ComfortEase garments provide patients with an effective system for at-home therapy and symptom relief of lymphedema, a condition which requires diligent daily management. Empowering Patients Through Digital Health Monitoring Patients using the Flexitouch Plus system, as well as those who are undiagnosed and concerned about their swelling, now have access to the Kylee mobile application. This application expands Tactile Medical’s ability to serve patients on their journey to diagnosis. Kylee, a personal lymphedema assistant, is available on both the iOS and Android platforms, and is intended to help educate, manage symptoms and support patients to help them get the most out of their therapies. The app enables users to record their symptoms and treatments, and upload photos to track changes over time. Kylee app users may also show their progress to their doctor, which can lead to more informed conversations. The free app includes Flexitouch Plus and Entre shipment and order tracking, product tutorial videos and an education library which provides helpful information about lymphedema and symptom management.
お知らせ • Jul 13Tactile Systems Technology, Inc. to Report Q2, 2022 Results on Aug 01, 2022Tactile Systems Technology, Inc. announced that they will report Q2, 2022 results at 4:00 PM, US Eastern Standard Time on Aug 01, 2022
お知らせ • Jun 26Tactile Systems Technology, Inc.(NasdaqGM:TCMD) dropped from Russell 2000 Defensive IndexTactile Systems Technology, Inc.(NasdaqGM:TCMD) dropped from Russell 2000 Defensive Index
Board Change • May 12High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director David Shafer was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • May 04First quarter 2022 earnings released: US$0.78 loss per share (vs US$0.12 loss in 1Q 2021)First quarter 2022 results: US$0.78 loss per share (down from US$0.12 loss in 1Q 2021). Revenue: US$48.0m (up 12% from 1Q 2021). Net loss: US$15.6m (loss widened US$13.3m from 1Q 2021). Over the next year, revenue is forecast to grow 16%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 42 percentage points per year, which is a significant difference in performance.
お知らせ • May 03Tactile Systems Technology, Inc. Reaffirms Earnings Guidance for the Year 2022Tactile Systems Technology, Inc. reaffirmed earnings guidance for the year 2022. The company continues to expect full year 2022 total revenue in the range of $235.0 million to $240.0 million, representing growth of approximately 13% to 15% year-over-year, compared to total revenue of $208.1 million in 2021.
お知らせ • Apr 01Tactile Systems Technology, Inc. to Report Q1, 2022 Results on May 02, 2022Tactile Systems Technology, Inc. announced that they will report Q1, 2022 results After-Market on May 02, 2022
お知らせ • Mar 29Tactile Systems Technology, Inc., Annual General Meeting, May 09, 2022Tactile Systems Technology, Inc., Annual General Meeting, May 09, 2022, at 09:00 Central Daylight. Agenda: To elect seven directors; to approve, on an advisory basis, the 2021 compensation of executive officers as disclosed in the ccompanying proxy statement; to ratify the appointment of grant thornton llp as independent registered public accounting firm for the year ending December 31, 2022; and to transact such other business as may properly come before the meeting or at any and all adjournments or postponements thereof.
Reported Earnings • Feb 24Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: US$0.60 loss per share (down from US$0.032 loss in FY 2020). Revenue: US$208.1m (up 11% from FY 2020). Net loss: US$11.8m (loss widened US$11.2m from FY 2020). Revenue exceeded analyst estimates by 1.8%. Over the next year, revenue is forecast to grow 14%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 46% per year whereas the company’s share price has fallen by 43% per year.
お知らせ • Feb 24Tactile Systems Technology, Inc. Provides Revenue Guidance for the Full Year 2022Tactile Systems Technology, Inc. provided revenue guidance for the full year 2022. For the year, the company expected total revenue in the range of $235.0 million to $240.0 million, representing growth of approximately 13% to 15% year-over-year, compared to total revenue of $208.1 million in 2021.
お知らせ • Feb 19Tactile Systems Technology, Inc. Announces Qui Tam Lawsuit Dropped by PlaintiffTactile Systems Technology, Inc. announced that the qui tam lawsuit filed by a competitor has been dropped and dismissed by a federal judge in Texas. The lawsuit challenged the propriety of Tactile Medical’s patient and physician education programs. This dismissal validates Tactile Medical’s longstanding confidence in the validity of its programs. Tactile Medical will not pay any damages, penalties, attorney fees or other compensation. With the claims dismissed by the federal judge, Tactile Medical also dismissed its remaining counterclaims. Tactile Medical will look forward to continuing to serve its patients through an industry-leading research and development and a comprehensive patient training program. Tactile Medical is committed to increasing awareness of lymphatic and vascular conditions through support of research and high-quality medical education, partnering with healthcare professionals, and most importantly, serving patients with dignity and care.
お知らせ • Jan 28Tactile Systems Technology, Inc. to Report Q4, 2021 Results on Feb 22, 2022Tactile Systems Technology, Inc. announced that they will report Q4, 2021 results After-Market on Feb 22, 2022
Valuation Update With 7 Day Price Move • Dec 09Investor sentiment improved over the past weekAfter last week's 16% share price gain to €19.30, the stock trades at a forward P/E ratio of 122x. Average forward P/E is 39x in the Medical Equipment industry in Germany. Total loss to shareholders of 58% over the past three years.
Valuation Update With 7 Day Price Move • Nov 15Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to €25.60, the stock trades at a forward P/E ratio of 171x. Average forward P/E is 39x in the Medical Equipment industry in Germany. Total loss to shareholders of 48% over the past three years.
Reported Earnings • Nov 09Third quarter 2021 earnings released: US$0.17 loss per share (vs US$0.13 profit in 3Q 2020)The company reported a soft third quarter result with weaker earnings and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: US$52.5m (up 6.9% from 3Q 2020). Net loss: US$3.36m (down 238% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.
お知らせ • Sep 10Tactile Systems Technology, Inc. (NasdaqGM:TCMD) acquired Substantially All of the Assets of AffloVest for $100 million.Tactile Systems Technology, Inc. (NasdaqGM:TCMD) acquired Substantially All of the Assets of AffloVest for $100 million on September 8, 2021. Tactile Systems Technology, Inc. (NasdaqGM:TCMD) will pay consideration of $80 million in cash, of which a total of $0.5 million was deposited into escrow accounts at closing for purposes of satisfying certain post-closing purchase price adjustments and indemnification claims, if needed. The International Biophysics Corporation may receive earn out payments of $20 million on the basis of certain revenue targets,$10 million based on revenues of the AffloVest during the 12 month period beginning on the first day of the calendar month following the closing, and up to $10.0 million based on revenues during the 12-month period thereafter. The transaction is financed through a combination of cash on hand and $55 million of borrowings under its existing credit facility, which is being amended in connection with this transaction. The acquisition is expected to be accretive to the Company’s adjusted EBITDA, excluding purchase accounting, non-cash amortization and transaction costs, by the end of year one post-closing. C. Walker Brierre of Holland & Knight LLP acted as a legal advisor to International Biophysics Corporation and Jonathan Zimmerman of Faegre Drinker Biddle & Reath LLP acted as a legal advisor to Tactile Systems Technology, Inc. (NasdaqGM:TCMD). Tactile Systems Technology, Inc. (NasdaqGM:TCMD) completed the acquisition of Substantially All of the Assets of AffloVest on September 8, 2021.
お知らせ • Aug 05Tactile Systems Technology, Inc. Revises Revenue Guidance for the Full Year 2021Tactile Systems Technology, Inc. revised revenue guidance for the full year 2021. The company now expected full year 2021 total revenue in the range of $216.3 million to $224.5 million, representing growth of approximately 16% to 20% year-over-year, compared to total revenue of $187.1 million in 2020. The company’s prior 2021 revenue guidance expectations called for total revenue in the range of $215.3 million to $224.5 million, representing an increase of 15% to 20%.
Reported Earnings • Aug 03Second quarter 2021 earnings released: EPS US$0.066 (vs US$0.72 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$51.1m (up 45% from 2Q 2020). Net income: US$1.31m (up US$15.2m from 2Q 2020). Profit margin: 2.6% (up from net loss in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has remained flat, which means it is well ahead of earnings.
Recent Insider Transactions • Jul 08President recently sold €125k worth of stockOn the 7th of July, Daniel Reuvers sold around 3k shares on-market at roughly €42.19 per share. This was the largest sale by an insider in the last 3 months. This was Daniel's only on-market trade for the last 12 months.